Northern RNA has announced the addition of Todd Howren, PhD, to its executive team in the newly created role of Chief Commercial Officer. With more than two decades of leadership in pharmaceutical business development and strategic alliances, Dr. Howren will spearhead the CDMO’s global commercial operations. His appointment aligns with Northern RNA’s ambition to expand its contract manufacturing services for RNA-based vaccines and therapeutics under current GMP standards. Based in Calgary, the company is positioning itself to meet surging demand from biotechnology innovators seeking specialized outsourcing partners for lipid nanoparticle formulation, mRNA synthesis, and fill-finish operations.
The Calgary manufacturing site operates multiple GMP-compliant suites designed for RNA drug substance production and downstream fill-finish processes. Equipped with modular clean rooms, single-use bioreactors ranging from 50 to 200 liters, and automated chromatography systems, Northern RNA supports both preclinical batches and large-scale clinical production. Recent investments in high-pressure homogenizers and nanoparticle encapsulation platforms have increased capacity by 40%, enabling contract manufacturers to scale from early-stage to commercial volumes without technology transfer delays. The facility also integrates advanced quality control labs for RNA integrity analysis, sterility testing, and real-time release assays, ensuring alignment with Health Canada and international regulatory guidelines.
The broader CDMO landscape is witnessing rapid expansion as the RNA therapeutics market grows at a double-digit CAGR driven by oncology, rare diseases, and vaccine development. Outsourcing to specialized CDMOs has become a strategic priority for biotechs aiming to accelerate time to market while managing capital expenditures. Regulatory authorities worldwide are updating guidelines to accommodate emerging RNA modalities, heightening demand for manufacturers with robust compliance track records. Northern RNA’s focus on end-to-end process development—from mRNA template design through lipid nanoparticle formulation and aseptic fill-finish—addresses key pain points in the supply chain by consolidating multiple contract steps under one roof.
Bringing Dr. Howren on board bolsters Northern RNA’s competitive stance by leveraging his extensive network among biotech innovators and global pharmaceutical firms. His experience in negotiating long-term supply agreements and forging cross-border partnerships will support the CDMO’s goal to secure multi-year contracts and expand its footprint into Europe and Asia. As companies increasingly outsource critical path activities to specialized partners, leadership versed in both scientific and commercial domains is essential. Under Dr. Howren’s guidance, Northern RNA aims to diversify its service offerings, explore strategic alliances for complementary biologics capabilities, and strengthen relationships with regulatory bodies to streamline project approvals.
Why This Matters
Securing a seasoned commercial executive underscores Northern RNA’s commitment to scaling its CDMO operations in line with global RNA manufacturing demand. Dr. Howren’s appointment enhances the company’s ability to attract high-value outsourcing projects, reinforce supply chain resilience, and navigate evolving regulatory landscapes. This leadership shift also signals increased competition among specialized CDMOs for pioneering RNA therapeutics and vaccine partnerships.
Key Takeaways
- Todd Howren, PhD, joins Northern RNA as Chief Commercial Officer to lead global CDMO sales and collaborations.
- Calgary facility now offers expanded GMP suites, single-use bioreactors, and advanced lipid nanoparticle formation to support RNA drug manufacturing at scale.
- The leadership hire strengthens Northern RNA’s position in a competitive CDMO market driven by growth in RNA-based therapeutics and vaccines.
Source: https://northernrna.com/todd-howren-phd-joins-northern-rna-as-chief-commercial-officer-cco/